Deals & Data
Sherpa Clinical Packing has opened a half million dollar facility in San Diego's Sorrento Valley area for labeling, packaging and distributing experimental drugs used in clinical trials, the start-up company said.
Genomatica appointed Michael Keane to be its first chief financial officer.
Optimer Pharmaceuticals launched the sale of its first commercial product, a prescription antibiotic for treating intestinal infection.
AnaptysBio announced the selection of a novel anti-IL17 monoclonal antibody (mAb) development candidate for the treatment of autoimmune and inflammatory conditions.
A second generic drug maker asked federal regulators to let it sell a lower-priced version of Ofirmev, an intravenous formulation of acetaminophen made by Cadence Pharmaceuticals.
Qualcomm promoted Matt Grob to executive vice president and chief technology officer (CTO).
San Diego DNA vaccine developer Vical will get up to $130 million for licensing the development and commercial rights for its experimental TransVax treatment to Astellas Pharma of Japan.
Cytori Therapeutics said it raised $6 million from a 1.3 million-share stock purchase agreement with East Coast-based Seaside 88 to fund European and U.S. stem cell therapy clinical trials in heart attack patients.
A food-surface disinfectant made by Pure Bioscience of El Cajon has received an important safety designation from the Food and Drug Administration.
San Diego drug maker Zogenix has teamed with Durect of Cupertino to develop a monthly needle-less injectable version of risperidone, a commonly prescribed treatment for schizophrenia.
Verenium, a San Diego biotechnology company that makes enzymes for industrial use, is moving across the highway from its office in the Sorrento Valley area to a new headquarters and laboratory in the Torrey Pines area, the company said.
A trio of biotechnology companies in San Diego County have been busy raising millions of dollars to buy back debt securities, finance acquisitions and continue the development of device that uses electricity to deliver cancer drugs
Life Technologies opened a regional hub in Bangalore, India to distribute their laboratory products.
San Diego-based Celladon, which is developing drug candidates that target a key enzyme deficiency apparent in heart failure, has secured $400,000 in a debt and securities financing.
Amgen and Micromet signed a deal, worth as much as $1.01 billion, to develop compounds against three cancer targets using the latter's BiTE antibody technology.
Fate Therapeutics, the high-profile stem cell startup in San Diego, has made some limited job cuts in recent months and changed strategy to focus on biotech drugs—instead of conventional small molecules—to coax stem cells into becoming a useful therapies.
Just five months after Cadence Pharmaceuticals started selling its first approved prescription drug, the San Diego company is facing potential competition from a pharmaceutical company that wants to sell a lower-priced, generic version of Ofirmev, an intravenous formulation of acetaminophen.
Sanofi partnered with Rib-X Pharmaceuticals to produce antibiotics under the latter's RX-04 clinical program, which targets multidrug-resistant Gram-positive and -negative bacteria.
Under the cross- and sub-licensing deals, Fluidigm gains access to PCR-related patents from Life Tech, which in return receives access to imaging readers and other technologies from Fluidigm.
ResMed, the San Diego maker of sleep-aid devices, said that it acquired BiancaMed, a privately owned Irish maker of sleep and breathing medical equipment.
In a move to boost its presence in Europe, San Diego medical equipment maker CareFusion said it has agreed to acquire German robotic medication storage and retrieval company Rowa for $150 million.
A scientist from The Scripps Research Institute has won a four-year, $1.9 million grant from the National Institutes of Health to better understand the parasite that causes malaria, laying the groundwork to develop better drugs to combat the widespread and deadly disease.
The National Institutes of Health awarded a $7.9 million grant to the Scripps Translational Science Institute (STSI) of San Diego and Sangamo BioSciences (of Richmond, Calif., to conduct the nation’s first-ever, heart-based “disease in a dish” research.
Shares of San Diego’s Amylin Pharmaceuticals gained more than 13 percent after the company’s experimental weekly type-2 diabetes drug, Bydureon showed no effect on heart rhythms in a crucial study that was ordered by the FDA.
Eli Lilly unveiled a multi-million dollar initiative to expand its biotech R&D in protein engineering, a move that includes hiring biochemists and biologists to work in “multi-specific therapeutics” in San Diego and Indianapolis.
Local drug developer, Sangart, has launched a second clinical study of its experimental drug MP4OX. The drug is meant to boost the delivery of oxygen in trauma patients who have lost large amounts of blood.
At the annual meeting of the American Society of Clinical Oncology, Tragara Pharmaceuticals reported impressive results from the recent Phase 2 trial of their lead experimental drug, Capoxigem.
Life Technologies has created a genetic test that is able to screen food for new E. coli bacteria, such as the type that recently killed over 22 people in Europe and sickened thousands more.
San Diego company Suneva Medical recently gained approval for the sale of their cosmetic wrinkle filler in Canada.
Researchers at San Diego’s Halozyme Therapeutics, along with partner company Baxter International, have created an injectable drug that may treat a certain type of immunodeficiency condition.
As of September, Lupus sufferers in Canada will be able to get the drug Benlysta, created by GlaxoSmithKline and Human Genome Sciences.